Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma.
Forlenza CJ, Rosenzweig J, Mauguen A, Buhtoiarov I, Cuglievan B, Dave H, Deyell RJ, Flerlage JE, Franklin AK, Krajewski J, Leger KJ, Marks LJ, Norris RE, Pacheco M, Willen F, Yan AP, Harker-Murray PD, Giulino-Roth L. Forlenza CJ, et al. Among authors: flerlage je. Blood Adv. 2023 Jul 11;7(13):3225-3231. doi: 10.1182/bloodadvances.2022009323. Blood Adv. 2023. PMID: 36897253 Free PMC article.
Expert consensus statements for Waldeyer's ring involvement in pediatric Hodgkin lymphoma: The staging, evaluation, and response criteria harmonization (SEARCH) for childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL) group.
Seelisch J, De Alarcon PA, Flerlage JE, Hoppe BS, Kaste SC, Kelly KM, Kurch L, Marks LJ, Mauz-Koerholz C, McCarten K, Metzger ML, Stroevesandt D, Voss SD, Punnett A. Seelisch J, et al. Among authors: flerlage je. Pediatr Blood Cancer. 2020 Sep;67(9):e28361. doi: 10.1002/pbc.28361. Epub 2020 Jul 16. Pediatr Blood Cancer. 2020. PMID: 32672879 Review.
Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
Metzger ML, Link MP, Billett AL, Flerlage J, Lucas JT Jr, Mandrell BN, Ehrhardt MJ, Bhakta N, Yock TI, Friedmann AM, de Alarcon P, Luna-Fineman S, Larsen E, Kaste SC, Shulkin B, Lu Z, Li C, Hiniker SM, Donaldson SS, Hudson MM, Krasin MJ. Metzger ML, et al. J Clin Oncol. 2021 Jul 10;39(20):2276-2283. doi: 10.1200/JCO.20.03286. Epub 2021 Apr 7. J Clin Oncol. 2021. PMID: 33826362 Free PMC article. Clinical Trial.
Pediatric Hodgkin Lymphoma, Version 3.2021.
Flerlage JE, Hiniker SM, Armenian S, Benya EC, Bobbey AJ, Chang V, Cooper S, Coulter DW, Cuglievan B, Hoppe BS, Isenalumhe L, Kelly K, Kersun L, Lamble AJ, Larrier NA, Magee J, Oduro K, Pacheco M, Price AP, Roberts KB, Smith CM, Sohani AR, Trovillion EM, Walling E, Xavier AC, Burns JL, Campbell M. Flerlage JE, et al. J Natl Compr Canc Netw. 2021 Jun 30;19(6):733-754. doi: 10.6004/jnccn.2021.0027. J Natl Compr Canc Netw. 2021. PMID: 34214968
Practice patterns for the management of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL): an international survey by the Global NLPHL One Working Group (GLOW).
Lo AC, Major A, Super L, Appel B, Shankar A, Constine LS, Marks LJ, Kelly KM, Metzger ML, Buhtoiarov IN, Mauz-Körholz C, Costa ARS, Binkley MS, Flerlage J. Lo AC, et al. Leuk Lymphoma. 2022 Aug;63(8):1997-2000. doi: 10.1080/10428194.2022.2053533. Epub 2022 Mar 31. Leuk Lymphoma. 2022. PMID: 35357263 No abstract available.
Discovery of novel predisposing coding and noncoding variants in familial Hodgkin lymphoma.
Flerlage JE, Myers JR, Maciaszek JL, Oak N, Rashkin SR, Hui Y, Wang YD, Chen W, Wu G, Chang TC, Hamilton K, Tithi SS, Goldin LR, Rotunno M, Caporaso N, Vogt A, Flamish D, Wyatt K, Liu J, Tucker M, Hahn CN, Brown AL, Scott HS, Mullighan C, Nichols KE, Metzger ML, McMaster ML, Yang JJ, Rampersaud E. Flerlage JE, et al. Blood. 2023 Mar 16;141(11):1293-1307. doi: 10.1182/blood.2022016056. Blood. 2023. PMID: 35977101 Free PMC article.
38 results